Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Arikayce (amikacin liposome inhalation suspension) for Mycobacterium avium complex (MAC) lung disease (full approval and label expansion)

Insmed · sNDA
FDA decision due
Jan 282027
72 days away
January has 4 FDA decisions on our calendar, this one included. Before it, Zeleciment rostudirsen on Jan 21st. After it, Joenja lower doses on Jan 30th.

The FDA is expected to decide on Arikayce for Mycobacterium avium complex (MAC) lung disease (full approval and label expansion) by January 28, 2027, under an sNDA from Insmed.

What the FDA is deciding on Arikayce for MAC

The FDA is reviewing Insmed's request to approve Arikayce (amikacin liposome inhalation suspension) for a new use, mycobacterium avium complex (MAC) lung disease (full approval and label expansion).

Priority review. Would convert the 2018 accelerated approval, which covers only refractory disease, to full approval, and Insmed says that could bring Arikayce to patients earlier in their disease course. The application rests on the Phase 3b ENCORE study in 425 adults with a new MAC lung infection, which met its main goal on respiratory symptoms at month 13.

Insmed reported on March 23, 2026 that sputum cultures cleared by month 6 in 87.8% of people on Arikayce plus standard antibiotics, against 57.0% on placebo plus standard antibiotics.

What an approval or a rejection of Arikayce would mean

An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.

A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.

Frequently asked questions

When will the FDA decide on Arikayce?

The FDA's target date (PDUFA date) for Arikayce in Mycobacterium avium complex (MAC) lung disease (full approval and label expansion) is January 28, 2027.

Who disclosed it: Insmed. The FDA does not publish these dates.

Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.

Source: Insmed announcement

What is Arikayce being reviewed for?

Insmed submitted an sNDA for Arikayce in Mycobacterium avium complex (MAC) lung disease (full approval and label expansion).

What to know: Priority review. Would convert the 2018 accelerated approval, which covers only refractory disease, to full approval, and Insmed says that could bring Arikayce to patients earlier in their disease course. The application rests on the Phase 3b ENCORE study in 425 adults with a new MAC lung infection, which met its main goal on respiratory symptoms at month 13. Insmed reported on March 23, 2026 that sputum cultures cleared by month 6 in 87.8% of people on Arikayce plus standard antibiotics, against 57.0% on placebo plus standard antibiotics.

How much will Arikayce cost?

Insmed has not announced a price. Drugmakers usually set it around approval.

Help paying: drugmaker programs and charity funds usually open at launch.

Find help: the patient assistance finder lists programs by insurance type.

What happens after the Arikayce decision?

This page updates with the outcome the day it is announced.

If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.

If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.

Where this date comes from

The FDA does not publish PDUFA dates; companies disclose them. This one comes from Insmed announcement. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.